JPX-0700 / Centessa, Eli Lilly - LARVOL DELTA

Dual specific STAT3/5 degraders effectively block acute myeloid leukemia and natural killer/T cell lymphoma. (PubMed, Hemasphere) - "We evaluated the efficacy of JPX-0700 and JPX-0750 as dual STAT3/5 binding inhibitors promoting protein degradation. Both JPX-0700/-0750 treatment reduced leukemic cell growth in human AML or NKCL xenograft mouse models significantly, being well tolerated by mice. Synergistic cell death was induced upon combinatorial use with approved chemotherapeutics in AML/NKCL cells."

Journal • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma • Targeted Protein Degradation • STAT3 • STAT5 • STAT5AWqe • STAT5B